GLUE Latest Headlines

Monte Rosa Therapeutics Secures $300 Million Through Underwritten Public Offering—What Does This Mean for GLUE?

Market Chameleon (Fri, 9-Jan 8:57 AM)

GLUE’s $200 Million Public Offering Proposal Spotlights Bold Expansion Strategy

Market Chameleon (Thu, 8-Jan 11:55 AM)

GLUE Jumps as Monte Rosa Readies Interim MRT-8102 Data: What Should Investors Watch Ahead of the Conference Call?

Market Chameleon (Wed, 7-Jan 9:54 AM)

GLUE’s MRT-8102 Shows 85% Reduction in Inflammatory Marker—Data Points to Broad Impact in CVD

Market Chameleon (Wed, 7-Jan 7:05 AM)

Monte Rosa’s MRT-2359 Delivers 100% Response in AR-Mutant Prostate Cancer—Next Phase 2 Study Set for 2026

Market Chameleon (Tue, 16-Dec 8:31 AM)